Aqua Nor 2011 Fish health
NOVARTIS celebrates 10th aquacultural anniversary
tion for an Infectious Salmon Anaemia (ISA) vaccine in North America, the fi rst commer- cialised ISA vaccine in Chile, the fi rst licensed nucleic acid vaccine for use in fi sh, and the APEX-IHN vaccine, which is the fi rst effective vaccine to prevent Infectious Haematopoietic Necrosis.
‘In addition to these innovative fi rsts, No- vartis has invested in meeting industry needs in other ways,’ Kamphuis said. ‘We recognise that working together with industry partners, both in academia and among our customers, is critical to driving successful aquaculture research and bringing new solutions to the market.’
Benefit
Two recent examples of these investments include the 2009 sponsorship of the Novartis Chair of Fish Health at the University of Prince Edward Island and their recent com- mitment to support the newly established Sea Lice Research Centre in Bergen. Such opportunities will, believes Kampius, benefi t both the company itself and the aquaculture industry at large.
Top: Robert Wilson starting the Novartis iPad prize draw at Aqua Nor
Above: Folkert Kamphius
NOVARTIS Animal Health (NAH) highlighted a key milestone in the company’s history at Aqua Nor – a decade of involvement in aquac- ulture. At the same time the company also an- nounced its latest expansion and investment plan, while the company’s Chief Operating Offi cer, Folkert Kamphuis, spoke about the past decade at a media briefi ng. ‘The acquisition of Vericore Holdings led to our stake in Cobequid Life Science, Inc and ultimately to the formation of the Novartis Aqua business in January 2001,’ Kamphuis recalled. ‘We have invested much more since then, based on our belief that the aquaculture industry has a very bright future and will play an increasingly important role in meeting society’s growing need for quality, farm-raised fi sh products.’
During its decade in aquaculture, the com- pany’s R&D efforts have delivered important industry breakthroughs, pointed out Kampius, which include the fi rst marketing authorisa-
Our current priority is towards our salmon farming customers
Fish Farmer September/October 2011 26
‘Novartis believes that we can be a strong and valuable industry partner in addressing the challenges facing the industry,’ Kamphuis concluded. ‘We look forward to more opportu- nities to support advancements and innova- tive solutions to management challenges.’ After the media briefi ng, Kamphuis spoke to Fish Farmer about the importance of aquacul- ture to Novartis Animal Health. ‘There is an obvious need for aquaculture to grow to meet rising demand for protein so we see this as an industry for the future. At the minute our priority is to service the needs of our salmon farming customers, solving the PD and sea lice problems fi rst. Aquacul- ture is a relatively young industry but it has progressed well over the last 40 years and will continue to progress as more species are domesticated,’ he refl ected. ‘Although aquaculture is currently a relatively small part of the overall Novartis Animal Health product portfolio, we see it as having great potential for growth. That is why we have committed relatively high R&D investment in aquaculture compared to other divisions. Of course it is a long-term process to develop animal health products but the process for fi sh will be the same as for other animals, and the need for solutions will only increase as aquaculture industrialises,’ he concluded.
www.fishfarmer-magazine.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52